GSK And Pfizer Start Consumer JV For Different Reasons, Aim For Similar Goals
Executive Summary
Big pharmas' agreement could put consumer health where Pfizer wants, entirely in its rear-view mirror, and points GSK toward what it wants, more research and development funding freed up for the pharmaceutical ingredient operations that are its chief revenue drivers. All-equity deal, giving GSK 68% control and expected to close in 2019 second half, also likely will boost investors' confidence in the firms as both have been dogged by pressure to sell, spin-off or otherwise divest their consumer businesses.
You may also be interested in...
Bayer And Consumer Health, Like Hand In Glove
“This is an amazing time to be in consumer health. Why would you get rid of an amazing business?” says Heiko Schipper, Bayer's consumer health chief since 2018.
J&J Rides Standalone Consumer Health Track
J&J takes same approach GSK, Pfizer, Merck & Co, Merck and Novartis have with their consumer health businesses, Bausch Health is starting and Sanofi says it will.
In AstraZeneca-Sponsored Study, Digital App Corrects OTC Statin Self-Selection Problem
Using web app for self-selection was successful with more than 95% concordance for the primary endpoint comparing results obtained by participants and independent clinical assessments, say researchers led by cardiologist and consumer health innovation advocate Steven Nissen.